Age Parameters for Tirzepatide
Tirzepatide is FDA-approved for adults aged 18 years and older for both type 2 diabetes and obesity/weight management, with emerging evidence supporting its use in adolescents aged 10 to <18 years for type 2 diabetes, and in older adults aged ≥65 years with comparable safety and efficacy profiles.
Adult Population (≥18 Years)
Tirzepatide received FDA approval in May 2022 for adults with type 2 diabetes (brand name Mounjaro) and in 2023 for obesity management (brand name Zepbound) 1. The medication is formulated as a once-weekly subcutaneous injection, titrated from a starting dose of 2.5 mg weekly to a maximum of 15 mg weekly 1.
For adults with obesity, tirzepatide demonstrates superior weight loss compared to GLP-1 receptor agonists alone, achieving 15-20% body weight reduction in clinical trials 2. In the SURMOUNT-1 trial, the highest dose (15 mg) resulted in an average weight reduction of 22.5% at 72 weeks, with nearly 40% of participants losing ≥25% of their body weight 1.
Pediatric Population (10 to <18 Years)
The SURPASS-PEDS trial established tirzepatide's efficacy and safety in youth aged 10 to <18 years with type 2 diabetes. This phase 3, double-blind, placebo-controlled trial enrolled 99 participants (mean age 14.7 years) with youth-onset type 2 diabetes inadequately controlled with metformin and/or basal insulin 3.
At week 30, tirzepatide demonstrated:
- Mean HbA1c reduction of 2.23% versus an increase of 0.05% with placebo (estimated treatment difference -2.28%; p<0.0001) 3
- BMI reductions of 7.4% and 11.2% for the 5 mg and 10 mg doses, respectively, compared with 0.4% in the placebo group 3
- Glycemic efficacy sustained up to 52 weeks 3
Real-world data from a multicenter retrospective study of 74 patients aged ≤21 years (median age 18.4 years) showed significant reductions in BMI, BMI z-score, weight, and HbA1c at first follow-up (median 102 days), with sustained improvements at second follow-up 4.
The safety profile in adolescents was consistent with adults, with the most common adverse events being gastrointestinal (mild to moderate severity) that decreased over time 3.
Older Adults (≥65 Years)
Post hoc analysis of the SURMOUNT and SUMMIT trials demonstrated that tirzepatide's efficacy and safety profiles in adults aged ≥65 years are comparable to those in adults <65 years 5. The analysis included participants from SURMOUNT-1 through -5, SURMOUNT-OSA, and SUMMIT trials.
Key findings in older adults:
- Clinically meaningful weight reduction with comparable results to younger adults 5
- No clinically meaningful differences in adverse event rates between tirzepatide and placebo for gastrointestinal tolerability, falls, fractures, depression outcomes, pancreatitis, and renal, hepatic, gallbladder and biliary-related adverse events 5
- No clinically relevant risks beyond those inherent to older age were detected 5
A real-world study (Hokkaido-TZP study) of 199 patients aged ≥65 years (mean age 71.3 years) showed significant reductions in both HbA1c and BMI over 6 months in both Young-old (65-74 years) and Old-old (≥75 years) groups 6. Importantly, physicians proactively adjusted concomitant hypoglycemia-inducing medications in 39.2% of users, and no severe hypoglycemia was reported 6.
Clinical Considerations by Age Group
For Adolescents (10 to <18 years):
- Currently approved only for type 2 diabetes, not obesity alone 3
- Randomization stratified by age group (≤14 years or >14 years) in clinical trials 3
- Requires inadequate control with metformin and/or basal insulin 3
For Older Adults (≥65 years):
- Preemptive dose reductions of concomitant secretagogues (insulin, sulfonylureas, glinides) are essential to prevent excessive HbA1c reduction and weight loss 6
- Careful monitoring required in this vulnerable population 6
- Lower tirzepatide doses may be appropriate for those achieving greater weight loss 6
Contraindications (All Ages):
- Personal or family history of medullary thyroid carcinoma 1, 7
- Multiple endocrine neoplasia type 2 1, 7
- History of severe gastrointestinal disease 2
The evidence supports tirzepatide use across a broad age spectrum from 10 years to ≥65 years, with age-appropriate monitoring and dose adjustments, particularly in older adults requiring concomitant diabetes medications.